Patients New hope for ovarian cancer, with Alexander Schneider Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.
Patients Precision medicine in action, with Cary Claiborne Cary Claiborne, CEO of Adial Pharmaceuticals, discusses his company’s bet on a precision treatment for AUD.
R&D Treating the chronic diseases GLP-1s miss, with Laurent Auda... Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Oncology A cancer treatment modality that prioritises QoL, with Ben Z... Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.